Prime Medicine

PRIME MEDICINE INC

First Trust Heitman Global Prime Real Estate ETF

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

July,30,,2019,Palo,Alto, - ,Ca, - ,Usa,-

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PRME

This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Cathie Wood Bets On Baidu As Chinese AI Buzz Intensifies, Ark Loads Up On $12.4 Million Worth Of Stock

Equities

ARKG

ARKK

PATH

RPTX

On April 11th, 2025, Cathie Wood&#39;s Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

Cathie Wood&#39;s Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

ETFs

ARKF

ARKW

CDNA

GTLB

IBTA

NTLA

RBLX

Ark Invest&#39;s Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.

Cathie Wood&#39;s Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta

Prime Medicine Inc

Health Care

Press Releases

Prime Medicine to Participate in Upcoming Investor Conferences

Earnings

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

General

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Management

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Anika Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cargo Therapeutics

Editas Medicine

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

INmune Bio

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

JMP Securities

Chardan Capital

Citizens Capital Markets

Guggenheim

Citigroup

Comments

Prime Medicine

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell